Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
18
CASI Quote, Financials, Valuation and Earnings
Last price:
$2.60
Seasonality move
:
4.5%
Day range:
$2.65 - $2.82
52-week range:
$2.05 - $8.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.67x
P/B ratio:
2.96x
Volume:
76.9K
Avg. volume:
45.4K
1-year change:
-59.17%
Market cap:
$41M
Revenue:
$33.9M
EPS (TTM):
-$2.24
Analysts' Opinion
-
Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, CASI Pharmaceuticals has an estimated upside of 126.42% from its current price of $2.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.65.
Fair Value
-
According to the consensus of 0 analysts, CASI Pharmaceuticals has 126.42% upside to fair value with a price target of -- per share.
CASI vs. S&P 500
-
Over the past 5 trading days, CASI Pharmaceuticals has underperformed the S&P 500 by -13.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CASI Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CASI Pharmaceuticals revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter CASI Pharmaceuticals reported revenues of $7.8M.
Earnings Growth
-
CASI Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter CASI Pharmaceuticals reported earnings per share of -$0.55.
Enterprise value:
39.3M
EV / Invested capital:
1.19x
Price / LTM sales:
1.67x
EV / EBIT:
--
EV / Revenue:
1.78x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$12M
Return On Assets:
-47.99%
Net Income Margin (TTM):
-140.3%
Return On Equity:
-137%
Return On Invested Capital:
-82.29%
Operating Margin:
-103.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $37M | $42.3M | $22.1M | $8.8M | $7.8M | |
| Gross Profit | $21.7M | $27M | $12M | $5.2M | $4M | |
| Operating Income | -$32.7M | -$26.9M | -$31.6M | -$5.2M | -$8.1M | |
| EBITDA | -$30.8M | -$26M | -$31.6M | -$5.2M | -$8.1M | |
| Diluted EPS | -$1.95 | -$3.01 | -$2.24 | -$0.35 | -$0.55 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $83.3M | $72M | $55.6M | $58.1M | $47.2M | |
| Total Assets | $134.2M | $136.3M | $127.9M | $74.2M | $63.6M | |
| Current Liabilities | $5.6M | $10M | $29.7M | $11.8M | $14.7M | |
| Total Liabilities | $21.4M | $26.8M | $44.7M | $23.8M | $49.8M | |
| Total Equity | $112.8M | $109.5M | $83.2M | $50.4M | $13.8M | |
| Total Debt | -- | $1.1M | $3M | -- | $19.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2021-12-31 | 2022-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.9M | -$26.8M | -$21.1M | -$7.6M | -$843K | |
| Cash From Investing | -$20.7M | -$20.7M | $31.2M | -$4.7M | $18M | |
| Cash From Financing | $47.2M | $29.6M | -$3.3M | -$1.1M | -$3.3M | |
| Free Cash Flow | -$45.2M | -$42.3M | -$26.7M | -$12.9M | -$4.3M | |
CASI
Sector
Market Cap
$41M
$43.9M
Price % of 52-Week High
32.36%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-59.17%
-29.11%
Beta (5-Year)
0.544
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.96
200-day SMA
Sell
Level
$4.74
Bollinger Bands (100)
Sell
Level
4.41 - 6.83
Chaikin Money Flow
Sell
Level
-163.2M
20-day SMA
Sell
Level
$3.48
Relative Strength Index (RSI14)
Sell
Level
29.16
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-90.3226
50-day SMA
Sell
Level
$4.82
MACD (12, 26)
Sell
Level
-0.62
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
142.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-11.1455)
Sell
CA Score
(Annual)
Level (-2.0949)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.8409)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Stock Forecast FAQ
In the current month, CASI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CASI average analyst price target in the past 3 months is --.
-
Where Will CASI Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that CASI Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About CASI Pharmaceuticals?
Analysts are divided on their view about CASI Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CASI Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is CASI Pharmaceuticals's Price Target?
The price target for CASI Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CASI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CASI Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CASI?
You can purchase shares of CASI Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CASI Pharmaceuticals shares.
-
What Is The CASI Pharmaceuticals Share Price Today?
CASI Pharmaceuticals was last trading at $2.60 per share. This represents the most recent stock quote for CASI Pharmaceuticals. Yesterday, CASI Pharmaceuticals closed at $2.65 per share.
-
How To Buy CASI Pharmaceuticals Stock Online?
In order to purchase CASI Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 0.02% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.7% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.65% over the past day.
